FGFR2 and neoplasm: When MSP was applied to tumour samples, a significant reduction of HOXD10, FGFR2 (P < 0.05), ITIH5 and RASAL3 (P < 0.001) promoter methylation was observed in DEC-treated mice (Fig 11).